APOE and Alzheimer disease: ApoE4 status and plasma p-tau217 (AD), NfL (neurodegeneration), GFAP and IL-6 (inflammation), GDF-15 (senescence/sarcopenia) will be evaluated in all subjects (n = 1,662) both at the baseline and at the end of the study (12 months).